NR1H4 and metabolic dysfunction-associated steatotic liver disease: Therefore, pharmacologic activation of Sirt1, Lxr and Fxr, which has been implicated in the pathogenesis of NAFLD, may be a potential therapeutic target for treating NAFLD.